Quince Therapeutics (QNCX) Projected to Post Quarterly Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Quince Therapeutics to post earnings of ($0.10) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.09). The company had revenue of $0.17 million during the quarter. On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Trading Down 4.5 %

Quince Therapeutics stock traded down $0.06 during mid-day trading on Thursday, hitting $1.26. The company's stock had a trading volume of 130,882 shares, compared to its average volume of 244,626. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The stock has a market cap of $55.44 million, a PE ratio of -1.02 and a beta of 0.71. The company has a 50 day moving average of $1.44 and a 200-day moving average of $1.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53.

Analyst Ratings Changes

Several research analysts recently commented on QNCX shares. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a "buy" rating and a $9.00 price target on the stock. D. Boral Capital reduced their target price on shares of Quince Therapeutics from $12.00 to $4.00 and set a "buy" rating on the stock in a research report on Tuesday, March 25th. Finally, Oppenheimer began coverage on Quince Therapeutics in a report on Monday, March 24th. They issued an "outperform" rating and a $10.00 price target for the company. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $8.00.

Remove Ads

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.